Latest Developments Of β-Nicotinamide Mononucleotide（NMN）

1. Core Global Regulatory Compliance

• US FDA: β-NMN is legally marketable as a dietary supplement (petition response on Sep 29). NPA's official confirmation on Dec 10 ends the 2022 compliance dispute. Leading enterprises (e.g., Kingdomway) have completed FDA compliance for overseas expansion.
• Australian TGA: NMN(CAS No.:1094-61-7) is included in the supplementary medicine list. PIC/S mutual recognition facilitates access to high-standard markets (UK, EU), accelerating global compliance.
•  Japan/Canada: Legality confirmed previously. Consensus on market access formed across major developed markets in 2025.

2. China's Policy & Industry Highlights 

•  Regulatory Status: Not approved as domestic health food yet; new cosmetic raw material filed in 2022; included in health food approval list in Apr 2025 (policy liberalization expected).
• Industry Advantage: China is the world's largest NMN raw material producer. Whole-enzyme/magnetic enzyme technologies reduce costs & improve quality (purity ≥99.9%). 2025 domestic raw material market scale: over RMB 3B (CAGR 18.2% 2021-2027).
•  Cross-Border Risk Alert: NMN addition to ordinary food prohibited in China; avoid medical claims (e.g., "anti-aging", "disease treatment"); cross-border sales must comply with import & platform regulations.

3. Key Tech & Market Points

• Tech Advancement: Whole-enzyme process mainstream; enteric-coated microcapsules & targeted delivery enhance bioavailability. NMNH, NADH & direct NAD+ supplementation are new competitive directions (long-term data pending).
• Market Trends: Shift from "content competition" to absorption efficiency, safety & long-term data. Compound formulations & population-specific products (Asians, gender-specific) are preferred.
• Purchasing Warnings: Prioritize β-NMN (purity ≥99.9%), FDA/TGA compliance & third-party test reports; guard against counterfeits (α-NMN passing as β-NMN) & unqualified products.